ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues

Rodney J. Hicks, Dik J. Kwekkeboom, Eric Krenning, Lisa Bodei, Simona Grozinsky-Glasberg, Rudolf Arnold, Ivan Borbath, Jaroslaw Cwikla, Christos Toumpanakis, Greg Kaltsas, Philippa Davies, Dieter Hörsch, Eva Tiensuu Janson, John Ramage

Research output: Contribution to journalArticlepeer-review

228 Citations (Scopus)

Abstract

The purpose of these guidelines is to assist physicians caring for patients with neuroendocrine neoplasia in considering eligibility criteria for peptide receptor radionuclide therapy (PRRT) and in defining the minimum requirements for PRRT. It is not these guidelines' aim to give recommendations on the use of specific radiolabelled somatostatin analogues for PRRT as different analogues are being used, and their availability is governed by varying international regulations. However, a recent randomized controlled trial, NETTER-1, has provided evidence that may establish 177Lu-DOTA-octreotate (LutaThera®) as the first widely approved agent. It also makes recommendations on what minimal patient, tumour, and treatment outcome characteristics should be reported for PRRT to facilitate robust comparisons between studies.

Original languageEnglish
Pages (from-to)295-309
Number of pages15
JournalNeuroendocrinology
Volume105
Issue number3
DOIs
Publication statusPublished - 1 Sept 2017

Keywords

  • Gastroenteropancreatic neuroendocrine tumour
  • Neuroendocrine tumour
  • Peptide receptor radionuclide therapy
  • Radiolabelled somatostatin analogues

Fingerprint

Dive into the research topics of 'ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Neoplasms: Peptide Receptor Radionuclide Therapy with Radiolabelled Somatostatin Analogues'. Together they form a unique fingerprint.

Cite this